hydroxyurea has been researched along with Ischemia in 10 studies
Ischemia: A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The full enrollment to REACH confirms the feasibility of conducting high-quality SCA research in Africa; this study will provide vital information to guide safe and effective dosing of hydroxyurea for children with SCA living in Africa." | 2.87 | Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa. ( Aygun, B; Howard, TA; Kitenge, R; Lane, A; Latham, T; Luís Reis da Fonseca, J; McElhinney, K; McGann, PT; Mochamah, G; Olupot-Olupot, P; Santos, B; Stuber, S; Tomlinson, GA; Tshilolo, L; Wabwire, H; Ware, RE; Williams, TN, 2018) |
| "Venous thrombosis is more frequent in PV than in ET; superficial or deep venous thromboses are seen." | 2.41 | [What vascular events suggest a myeloproliferative disorder?]. ( Caulier-Leleu, MT; Hachulla, E; Pasturel-Michon, U; Rose, C; Trillot, N, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Joice, GA | 1 |
| Liu, JL | 1 |
| Burnett, AL | 1 |
| McGann, PT | 1 |
| Williams, TN | 1 |
| Olupot-Olupot, P | 1 |
| Tomlinson, GA | 1 |
| Lane, A | 1 |
| Luís Reis da Fonseca, J | 1 |
| Kitenge, R | 1 |
| Mochamah, G | 1 |
| Wabwire, H | 1 |
| Stuber, S | 1 |
| Howard, TA | 1 |
| McElhinney, K | 1 |
| Aygun, B | 1 |
| Latham, T | 1 |
| Santos, B | 1 |
| Tshilolo, L | 1 |
| Ware, RE | 1 |
| Fourgeaud, C | 1 |
| El Nemer, W | 1 |
| Michon Pasturel, U | 1 |
| Bonhomme, S | 1 |
| Brignier, A | 1 |
| Lazareth, I | 1 |
| Priollet, P | 1 |
| Krishnan, R | 1 |
| Economopoulou, M | 1 |
| Langer, HF | 1 |
| Celeste, A | 1 |
| Orlova, VV | 1 |
| Choi, EY | 1 |
| Ma, M | 1 |
| Vassilopoulos, A | 1 |
| Callen, E | 1 |
| Deng, C | 1 |
| Bassing, CH | 1 |
| Boehm, M | 1 |
| Nussenzweig, A | 1 |
| Chavakis, T | 1 |
| Lukina, EA | 1 |
| Sysoeva, EP | 1 |
| Kitsenko, EA | 1 |
| Varlamova, EIu | 1 |
| Inozemtseva, MV | 1 |
| Semenova, EA | 1 |
| Nadinskaia, MIu | 1 |
| Ivashkin, VT | 1 |
| Patel, NS | 1 |
| Cuzzocrea, S | 1 |
| Chatterjee, PK | 1 |
| Di Paola, R | 1 |
| Sautebin, L | 1 |
| Britti, D | 1 |
| Thiemermann, C | 1 |
| McLornan, D | 1 |
| McMullin, M | 1 |
| Hachulla, E | 1 |
| Rose, C | 1 |
| Trillot, N | 1 |
| Caulier-Leleu, MT | 1 |
| Pasturel-Michon, U | 1 |
| Finazzi, G | 1 |
| Barbui, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| REALIZING EFFECTIVENESS ACROSS CONTINENTS WITH HYDROXYUREA (REACH): A PHASE I/II PILOT STUDY OF HYDROXYUREA FOR CHILDREN WITH SICKLE CELL ANEMIA[NCT01966731] | Phase 1/Phase 2 | 635 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
An expected toxicity rate of 20% and acceptable toxicity rate of 30% were used for statistical calculations. After 53 participants at each site complete 3 months of therapy, if ≤ 15 participants have hematologic toxicity there is no early evidence against safety. If ≥ 15 of the initial participants experience toxicity, this is early evidence against safety. Future participants will begin at a lower dose of hydroxyurea (10 ± 2.5 mg/kg), with another 53 participants recruited of the same safety analysis. Upon final analysis of 133 participants at the same starting dose, safety for fixed-dose hydroxyurea can be concluded. (NCT01966731)
Timeframe: 3 months
| Intervention | percentage of participants (Number) |
|---|---|
| Hydroxyurea | 5.1 |
5 reviews available for hydroxyurea and Ischemia
| Article | Year |
|---|---|
Medical treatment of recurrent ischaemic priapism: a review of current molecular therapeutics and a new clinical management paradigm.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Agonists; Adrenergic beta-Agonists; Algori | 2021 |
[Vascular myeloproliferative neoplasm with normal cell blood count: Exploration and medical management].
Topics: Aged; Blood Cell Count; Bone Marrow; Cell Adhesion; Cell Adhesion Molecules; Comorbidity; Diagnosis, | 2015 |
How would I manage a case of essential thrombocythaemia presenting with an ischaemic toe.
Topics: Aspirin; Evidence-Based Medicine; Humans; Hydroxyurea; Interferon-alpha; Ischemia; Janus Kinase 2; M | 2008 |
[What vascular events suggest a myeloproliferative disorder?].
Topics: Adult; Aged; Alkylating Agents; Arterial Occlusive Diseases; Cross-Sectional Studies; Erythromelalgi | 2000 |
Efficacy and safety of hydroxyurea in patients with essential thrombocythemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Cell Transformation, Neoplastic; Cohort Studies; Female; Fol | 2001 |
1 trial available for hydroxyurea and Ischemia
| Article | Year |
|---|---|
Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa.
Topics: Africa South of the Sahara; alpha-Thalassemia; Anemia, Sickle Cell; Blood Transfusion; Child; Child, | 2018 |
4 other studies available for hydroxyurea and Ischemia
| Article | Year |
|---|---|
Peripheral retinal neovascularization associated with polycythemia rubra vera.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizuma | 2009 |
Histone H2AX is integral to hypoxia-driven neovascularization.
Topics: Animals; DNA Damage; Endothelium, Vascular; Gene Deletion; Hindlimb; Histones; Humans; Hydroxyurea; | 2009 |
[Syndrome of extrahepatic portal hypertension and chronic abdominal ischemia in patient with subleukemic myelosis and congenital immunodeficiency].
Topics: Abdomen; Adult; Anticoagulants; Antineoplastic Agents; Chronic Disease; Female; Humans; Hydroxyurea; | 2009 |
Reduction of renal ischemia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton.
Topics: Animals; Arachidonate 5-Lipoxygenase; Disease Models, Animal; Hydroxyurea; Inflammation; Intercellul | 2004 |